Creative Medical Technology
CELZ
15 hedge funds and large institutions have $541K invested in Creative Medical Technology in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1,006% more capital inflows, than outflows
Capital inflows: $657K | Capital outflows: $59.4K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
36% more funds holding
Funds holding: 11 → 15 (+4)
7.47% more ownership
Funds ownership: 2.62% → 10.09% (+7.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$292K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$228K |
| 3 |
Armistice Capital
New York
|
+$90.7K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$26.5K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$5.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$27K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.6K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$10.3K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$515 |
| 5 |
Morgan Stanley
New York
|
-$43 |
CELZ Hedge Fund Activity: Q2 2026 in Review
15 of the 8,353 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q2 2026, worth a combined $541K — up 171% from $199K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CELZ positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $292K. The largest seller was Geode Capital Management, cutting an estimated $27K.
- 15 institutional investors held Creative Medical Technology (CELZ) as of Q2 2026, up from 11 in Q1 2026.
- Funds reported $541K of Creative Medical Technology stock for Q2 2026, up 171% quarter-over-quarter.
- 7 funds opened new Creative Medical Technology positions in Q2 2026 and 3 closed out, a net change of +4 holders.
- The largest Creative Medical Technology buyer in Q2 2026 was Hudson Bay Capital Management, an estimated $292K added.
- The largest Creative Medical Technology seller in Q2 2026 was Geode Capital Management, an estimated $27K sold.
Based on aggregated 13F filings for Q2 2026.